Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Sutro Biopharma (STRO) Income from Continuing Operations (2017 - 2025)

Sutro Biopharma's Income from Continuing Operations history spans 9 years, with the latest figure at 49196000.0 for Q3 2025.

  • For Q3 2025, Income from Continuing Operations fell 0.84% year-over-year to 49196000.0; the TTM value through Sep 2025 reached 202969000.0, down 63.74%, while the annual FY2024 figure was 227461000.0, 112.98% down from the prior year.
  • Income from Continuing Operations for Q3 2025 was 49196000.0 at Sutro Biopharma, down from 11517000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 31057000.0 in Q4 2023 and bottomed at 72443000.0 in Q4 2024.
  • The 5-year median for Income from Continuing Operations is 38524000.0 (2023), against an average of 35964421.05.
  • The largest annual shift saw Income from Continuing Operations soared 189.78% in 2023 before it crashed 333.26% in 2024.
  • A 5-year view of Income from Continuing Operations shows it stood at 38125000.0 in 2021, then increased by 9.26% to 34594000.0 in 2022, then skyrocketed by 189.78% to 31057000.0 in 2023, then crashed by 333.26% to 72443000.0 in 2024, then surged by 32.09% to 49196000.0 in 2025.
  • Per Business Quant, the three most recent readings for STRO's Income from Continuing Operations are 49196000.0 (Q3 2025), 11517000.0 (Q2 2025), and 69813000.0 (Q1 2025).